Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Fineline Cube Mar 10, 2026
Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Fineline Cube Mar 10, 2026
Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Fineline Cube Mar 10, 2026
Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Company Deals

GE Healthcare and Sutter Health Form $1B Care Alliance

Fineline Cube Jan 16, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...

Company Drug

HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China

Fineline Cube Jan 16, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer

Fineline Cube Jan 16, 2025

China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...

Company Drug

Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial

Fineline Cube Jan 16, 2025

China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...

Company Drug

Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment

Fineline Cube Jan 16, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors

Fineline Cube Jan 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...

Legal / IP

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Fineline Cube Jan 16, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...

Company Deals

Biogen Proposes to Acquire Sage Therapeutics for $469M

Fineline Cube Jan 15, 2025

US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...

Company Deals Medical Device

Medtronic Secures Exclusive Distribution Rights for Contego’s Neuroguard and Excipio

Fineline Cube Jan 15, 2025

US-Irish firm Medtronic (NYSE: MDT) has entered into an exclusive distribution agreement with Contego Medical,...

Company Deals

Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B

Fineline Cube Jan 15, 2025

US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from...

Company Deals

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B

Fineline Cube Jan 15, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...

Company Deals

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline

Fineline Cube Jan 15, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has entered into an agreement with US-based biopharma IDRx, Inc....

Company Deals

Autobio Diagnostics Partners with Boditech Med for Korean IVD Market

Fineline Cube Jan 15, 2025

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered...

Company Deals

Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug

Fineline Cube Jan 15, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott...

Company Drug

Chongqing Genrix’s Silevimig NDA Accepted for Rabies Immunization Review

Fineline Cube Jan 15, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) has announced that a New Drug...

Legal / IP

Novartis to Defend Entresto Patent After CAFC Ruling

Fineline Cube Jan 14, 2025

Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...

Company Deals

Bristol-Myers Squibb Exercises License for ArsenalBio’s AB-4000 Series

Fineline Cube Jan 14, 2025

US-based cell therapy company Arsenal Biosciences, Inc. has announced that Bristol-Myers Squibb (BMS, NYSE: BMY)...

Company Drug

Hengrui and Kailera Announce Positive Phase II Results for HRS9531 in Weight Loss

Fineline Cube Jan 14, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Posts pagination

1 … 192 193 194 … 632

Recent updates

  • NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile
  • HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor
  • Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors
  • Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity
  • Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Company Drug

Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.